5G and GMO: Electromagnetic Waves and Genetic Engineering: Profit Driven Destruction

JULIAN ROSE | February 25, 2019

article image
We know that the genetic engineering of the plant and animal kingdom alters their DNA, and does the same to those who regularly ingest GM foods. People, animals, fish, insects and plants that absorb or are cross contaminated by other genetically modified species, are the victims of the recombinant DNA laboratory techniques used in genetic engineering. It’s not for nothing that the engineered produce that emerges out of this process earned the title ‘Frankenstein Food’. But, as GMO hit the fields, another Frankenstein was in development that was to have its own special set of devastating consequences for life on this planet: Electro Magnetic Frequencies (EMF). 

Spotlight

Hematogenix

Hematogenix is an oncology diagnostic services company founded by physicians to help physicians. While we pride ourselves in the aid we provide to our clients; patient care is our priority. We exist to improve patient care, and we are dedicated to that cause. Hematogenix provides a complete menu of services such as Molecular Tumor Profiling, Flow Cytometry, FISH analysis, Cytogenetics, Molecular Diagnostics, Bone Marrow Morphology and more. Our test menu reflects our commitment to utilizing the most advanced techniques to enhance patient care.

OTHER ARTICLES

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Spotlight

Hematogenix

Hematogenix is an oncology diagnostic services company founded by physicians to help physicians. While we pride ourselves in the aid we provide to our clients; patient care is our priority. We exist to improve patient care, and we are dedicated to that cause. Hematogenix provides a complete menu of services such as Molecular Tumor Profiling, Flow Cytometry, FISH analysis, Cytogenetics, Molecular Diagnostics, Bone Marrow Morphology and more. Our test menu reflects our commitment to utilizing the most advanced techniques to enhance patient care.

Events